Tau PET Imaging in Atypical Dementias

The University of Chicago

Status and phase: Completed; Phase 1

Conditions: Primary Progressive Aphasia With Suspected Alzheimer's Disease

Treatments: Device: PET; Drug: 18F-AV-1451

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT03283449

IRB23-1338

R01AG056258 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.

Enrollment: 70 estimated patients

Sex: All

Ages: 20 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have primary progressive aphasia

Exclusion criteria

• Pregnancy
• Breastfeeding
• Receiving radiation clinically

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

70 participants in 1 patient group

AV-1451 Recipients

Experimental group

Description:

Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.

Treatment:

Drug: 18F-AV-1451

Device: PET